



Substitute for form 1449A/B/PTO

Complete If Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			
Sheet	1	of	3
			Attorney Docket Number
			ASZD-P01-837

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
NG	AA*	US-2004/0048878-A1	03-11-2004	Cai et al.	
NG	AB*	US-2004/0220229-A1	11-04-2004	Bussolotti et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
NG	BA	EP-1088824 A2	04-04-2001			
NG	BB	EP-1136071 A3	03-26-2003			
NG	BC	WO-1994/18196 A1	08-18-1994			
NG	BD	WO-2001/28993 A2	04-26-2001			
NG	BE	WO-2002/06246 A1	01-24-2002			
NG	BF	WO-2002/20530 A1	03-14-2002			
NG	BG	WO-2003/074484 A1	09-12-2003			
NG	BH	WO-2003/074485 A2	09-12-2003			
NG	BI	WO-2003/074513 A2	09-12-2003			
NG	BJ	WO-2003/074517 A1	09-12-2003			
NG	BK	WO-2003/074531 A1	09-12-2003			
NG	BL	WO-2003/074532 A1	09-12-2003			
NG	BM	WO-2003/091213 A1	11-06-2003			
NG	BN	WO-2004/041780 A2	05-21-2004		Abstract only	
NG	BO	WO-2004/058715 A1	07-15-2004			
NG	BP	WO-2004/113345 A1	12-29-2004			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
NG	CA	Adams et al., "4-Amino-4,5-dihydrothiophene-2-carboxylic acid," J. Org. Chem. 50:2730-2736 (1985)	
NG	CB	Binder et al., "Eine einfache herstellungsmethode fur 2-aminothiophene," Synthesis Communications 4:255-256 (1977)	
NG	CC	Binder et al., "Thiopen als strukturelement physiologisch aktiver substanzen, 8. mitt. 1H5H-imidazo[1,2-a]thieno[3,4-d]pyrimidin-2(3H-one," Arch Pharm. 314:556-564 (1981)	
NG	CD	Bjork et al., "Improved syntheses of thiolo[2,3-b]- and [3,2-b]-fused naphthyridines," J. Heterocyclic Chem. 32:751-754 (1995)	

Examiner Signature	/Nyeemah Grazier/	Date Considered	02/16/2007
--------------------	-------------------	-----------------	------------

Substitute for form 1449A/B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/528612
(Use as many sheets as necessary)				Filing Date	March 21, 2005
				First Named Inventor	Michael Butters
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	ASZD-P01-837

NG	CE	Boger et al., "Total synthesis of distamycin A and 2640 analogues: A solution-phase combinatorial approach to the discovery of new, bioactive DNA binding agents and development of a rapid, high-throughput screen for determining relative DNA binding affinity or DNA binding sequence selectivity," <i>J. Am. Chem. Soc.</i> 122:6382-6394 (2000)	
NG	CF	Brugier et al., "α-Substitution of β-thienylcarbamates: alkylation, vinylation and Pd-catalyzed coupling reactions," <i>Tetrahedron</i> 56:2985-2993 (2000)	
NG	CG	Brugier et al., "Studies on the reactivity of N-(3-thienyl)carbamates," <i>J. Chem. Soc., Perkin Trans. 1</i> :37-43 (2001)	
NG	CH	Brugier et al., "Synthesis and reactivity of alkyl (4-aminothien-3-yl)carbamates," <i>Tetrahedron</i> 53(30):10331-10344 (1997)	
NG	CI	Brunnett et al., "Heterocyclic amines. IV. Urethan and urea derivatives of 3-aminothiophene (1)," <i>J. Heterocyclic Chem.</i> 5(3):417-418 (1968)	
NG	CJ	Carroll et al., "Competitive ortho metalation effects: the kinetic and thermodynamic lithiation of 3-(tert-Butoxycarbonyl)amino-4-caromethoxythiopene," <i>Tetrahedron Letters</i> 38(15):2637-2640 (1997)	
NG	CK	Eras et al., "Reactivity of theinopyrroles. synthesis of isomeric nitro and bromothienopyrroles," <i>J. Heterocyclic Chem.</i> 21:215-217 (1984)	
NG	CL	Galvez et al., "Synthesis of isomeric β-haloethylthienopyrroles," <i>J. heterocyclic Chem.</i> , 21, 393-395 (1984)	
NG	CM	Galvez et al., "Synthesis of thiophenedicarbonyldiazides and Di-t-butyl thiophendicarbamates," <i>J. Heterocyclic Chem.</i> 23:1103-1108 (1986)	
NG	CN	Jones et al., "The vilsmeier reaction of fully conjugated carbocycles and heterocycles," <i>Organic Reactions</i> 49:1-39 (1997)	
NG	CO	Kobayashi et al., "Heterocyclic sulfonyl compounds and activated blood coagulation factor X (FXa) inhibitors containing them," <i>Chemical Abstracts</i> XP002267904 & JP 2001 294572 (2001)	
NG	CP	Linda et al., "The mechanism of the Vilsmeier-Haack reaction. Part III. Structural and solvent effects," <i>J. Chem. Soc. Perkins Trans II</i> , 1610-1612 (1974)	
NG	CQ	Marques et al., "Toward an understanding of the chemical etiology for DNA minor-groove recognition by polyamides," <i>Helvetica Chimica Acta</i> 85:4485-4517 (2002)	
NG	CR	Martin et al., "Nucelar magnetic resonance investigations of carbonium ion intermediates. Part II. Exchange reactions in chloro-iminium salts (Vilsmeier-Haack reagents)," <i>Journal Chem. Soc., Perkins Trans II</i> 642-646 (1974)	
NG	CS	Martin et al., "Recherches sur la reaction de vilsmeier-haack etude du mecanisme de formation du complexe par des mesures cinetiques en resonance magnetique nucleaire," <i>Tetrahedron Letters</i> 58:5061-5064 (1970)	
NG	CT	Meth-Cohn et al., "A versatile new synthesis of quinolines and related fused pyridines. Part II," <i>Tetrahedron Letters</i> 33:3111-3114 (1979)	
NG	CU	Meth-Cohn et al., "A versatile new synthesis of quinolines and related fuses pyridines. Part 7. The conversion of acetamidothiophens into thienopyridines," <i>Journal Chem. Soc., Perkins Trans. I</i> 1531-1536 (1981)	
NG	CV	Meth-Cohn et al., "A versatile new synthesis of quinolines, thienopyridines and related fused pyridines," <i>Tetrahedron Letters</i> 23:2045-2048 (1978)	
NG	CW	Meth-Cohn et al., "The preparation and formylation of 2-acetamidothiophenes," <i>Synthesis</i> 2:133-135 (1980)	
NG	CX	Nakamura, "Construction of heterocyclic compounds by use of alpha-diazaphosphonates: new one-pot syntheses of indoles and isocoumarines," <i>Organic Letters</i> 4(14)2317-2320 (2002)	

Examiner Signature	/Nyeemah Grazier/	Date Considered	02/16/2007
--------------------	-------------------	-----------------	------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<i>Complete If Known</i>	
				Application Number	10/528612
				Filing Date	March 21, 2005
				First Named Inventor	Michael Butters
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	ASZD-P01-837

NG	CY	Rajanna et al., "Kinetics and mechanism of Vilemeier-Haach synthesis of 3-formyl chromones derived from o-hydroxy aryl alkyl ketones: A structure reactivity study," <i>Tetrahedron</i> 52(10):3669-3682 (1996)	
NG	CZ	Seela et al., "168. Synthesis of 2'-deoxyribofuranosides of 8-Aza-7-deazaguanine and related pyrazolo[3,4-d]pyrimidines," <i>Helvetica Chimica Acta</i> 69:1602-1613 (1986)	
NG	CA1	Shinkwin et al., "Synthesis of thiophenecarboxamides, thieno[3,4-c]pyridin-4(5H)-ones and Thieno[3,4-d]pyrimidin-4(3H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP)," <i>Bioorganic & Medicinal Chemistry</i> 7:297-308 (1999)	
NG	CB1	Shvedov et al., "2-Aminothieno[2,3-b]pyridine derivatives, Chemical Abstracts, XP002266826 & SU364613 (1973)	
NG	CC1	Soth et al., "Recherches en serie heterocyclique. XXIX. Sur des voies d'accès à des thieno, selenolo, furo et pyrrolopyrroles," <i>Canadian Journal of Chemistry</i> 56(6):1429-1434 (1978)	
NG	CD1	Stanetty et al., "Herbicide thienylhamstoffe, I," <i>Monatshefte für Chemie</i> 120:53-63 (1989)	
NG	CE1	Sugiyama et al., "Condensed thienopyrimidines. IV. Synthesis and gastric antisecretory activity of 2,3-dihydro-5H-oxazolothienopyrimidine derivatives," <i>Chemical & Pharmaceutical Bulletin</i> 37(10):2171-2722 (1989)	
NG	CF1	Sugiyama et al., "Condensed thienopyrimidines. 5. Studies on the thermal cyclization of various ortho-formylthiophenecarbamates with ethanolamine," <i>Heterocycles</i> 29(7):1317-1323 (1989)	
NG	CG1	Szabo et al., "Experimental and theoretical study of orientation in the nitration of dithieno[3,4-b:3',4'-d]pyridine," <i>J. Organic Chem</i> 56:1590-1596 (1991)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Nyeemah Grazier/	Date Considered	02/16/2007
--------------------	-------------------	-----------------	------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<i>101528612</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete If Known	
(Use as many sheets as necessary)				Application Number	Not Yet Assigned
Sheet	1	of	2	Filing Date	March 21, 2005
				First Named Inventor	Michael Butters
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	ASZD-P01-837

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
NG	BA	WO-94/18196 A	08-18-1994		
NG	BB	WO-02/06246 A	01-24-2002		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
NG	CA	Adams et al., "4-Amino-4,5-dihydrothiophene-2-carboxylic acid," Journal of Organic Chemistry 50(15):2730-2736 (1985)			
NG	CB	Binder et al., "Thiophen als a Strukturelement physiologisch aktiver Substanzen, 8. Mitt. 1H, 5H-Imidazo '1,2-althieno'3,4-dipyrimidin - 2(3H)-one," Archiv der Pharmazie 314(6):556-564 (1981)			
NG	CC	Bjørk et al., "Improved synthesis of thieno '2,3-bl-and '3,2-bl-fused naphthyridines," Journal of Heterocyclic Chemistry 32(3):751-754 (1995)			
NG	CD	Boger et al., "Total synthesis of distamycin A and 2640 analogs: A solution-phase combinatorial approach to the discovery of new, bioactive DNA binding agents and development of a rapid high-throughput screen for determining relative DNA binding affinity or DNA binding sequence selectivity," Journal of the American Chemical Society 122(27):6382-6394 (2000)			
NG	CE	Brugier et al., ".alpha.-substitution of .beta.-thienylcarbamates: alkylation, vinylation and Pd-catalyzed coupling reactions," Tetrahedron 56(19):2985-2993 (2000)			
NG	CF	Brugier et al., "Synthesis and reactivity of alkyl (4-amino-3-thienyl)carbamates," Tetrahedron 53(30):10331-10344 (1997)			
NG	CG	Brugier et al., "Studies on the reactivity of N-(3-thienyl)carbamates," Journal of the Chemical Society, Perkin Transactions 1 1:37-43 (2001)			
NG	CH	Brunnett et al., "Heterocyclic amines. IV. Urethan and urea derivatives of 3-aminothiophene," Journal of Heterocyclic Chemistry 5(3):417-418 (1968)			
NG	CI	Carroll et al., "Competitive ortho metalation effects: the kinetic and thermodynamic lithiation of 3-(tert-butoxycarbonyl)amino-4-carbomethoxy thiophene," Tetrahedron Letters 38(15):2637-2640 (1997)			
NG	CJ	Galvez et al., "Synthesis of isomeric .beta.-haloethylthienopyrroles," Journal of Heterocyclic Chemistry 21(2):393-395 (1984)			
NG	CK	Galvez et al., "Synthesis of thiophenedicarbonyldiazides and di-t-butyl thiophendicarbamates," Journal of Heterocyclic Chemistry 23:1103-1108 (1986)			

Examiner Signature	/Nyeemah Grazier/	Date Considered	02/16/2007
--------------------	-------------------	-----------------	------------

JC05 Rec'd PCT/PTO 21 MAR 2005

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Prior Art 107528612	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	Not Yet Assigned
<i>(Use as many sheets as necessary)</i>				Filing Date	March 21, 2005
				First Named Inventor	Michael Butters
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	ASZD-P01-837

NG	CL	Kobayashi et al., "Heterocyclic sulfonyl compounds and activated blood coagulation factor X (FXa) inhibitors containing them," Database CA 'online! Chemical Abstracts Service, Database accesión no. 135:313616 XP002267904 368442-47-1 and JP 2001 294572 A (2001)	
NG	CM	Marques et al., "Toward an understanding of the chemical etiology for DNA minor-groove recognition by polyamides," Helvetica Chimica Acta 85(12):4485-4517 (2002)	
NG	CN	Shinkwin et al., "Synthesis of thiophenecarboxamides, thieno '3,4-c'pyridiin-4(5H)-ones and thieno '3,4-d'pyrimidin-4(3H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP)," Bioorganic & Medicinal Chemistry 7(2):297-308 (1999)	
NG	CO	Soth et al., "Recherches en serie heterocyclique. XXIX. Sur des voies d'accès à des thieno, selenolo, furo et pyrrolopyrroles," Canadian Journal of Chemistry 56(6):1429-1434 (1978)	
NG	CP	Szabo et al., "Experimental and theoretical study of orientation in the nitration of dithieno '3,4-b:3',4'-dipyridine," Journal of Organic chemistry 56(4):1590-1596 (1991)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Nyeemah Grazier/	Date Considered	02/16/2007
--------------------	-------------------	-----------------	------------

IDS - 04/17/2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Not for submission under 37 CFR 1.99)</small>	Application Number		10528612
	Filing Date		2005-03-21
	First Named Inventor		Michael Butters
	Art Unit		1626
	Examiner Name		GRAZIER, NYEEMAH
	Attorney Docket Number		100837-1P US

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
NG	1	20040142938		2004-07-22	Sher et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
NG	1	03/072570	WO	A1	2003-09-04	Pfizer Products Inc.		<input type="checkbox"/>
NG	2	1 340 500	EP	A1	2003-09-03	Pfizer Products Inc.		<input type="checkbox"/>
NG	3	2004/092158	WO	A1	2004-10-28	Pfizer Products Inc.		<input type="checkbox"/>

/Nyeemah Grazier/

02/16/2007

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Application Number		10528612	
		Filing Date		2005-03-21	
		First Named Inventor		Michael Butters	
		Art Unit		1626	
		Examiner Name		GRAZIER, NYEEMAH	
		Attorney Docket Number		100837-1P US	

NG	4	2004196702	JP	A	2004-07-15	Yamanouchi Pharmaceutical Co., Ltd.	<input checked="" type="checkbox"/>
NG	5	01/32622	WO	A1	2001-05-10	AstraZeneca AB	<input type="checkbox"/>
NG	6	2004/031194	WO	A1	2004-04-15	AstraZeneca AB	<input type="checkbox"/>
NG	7	2005/013981	WO	A1	2005-02-17	AstraZeneca AB	<input type="checkbox"/>
NG	8	2005/013975	WO	A1	2005-02-17	AstraZeneca AB	<input type="checkbox"/>
NG	9	2005/020986	WO	A1	2005-03-10	AstraZeneca AB	<input type="checkbox"/>
NG	10	2005/020985	WO	A1	2005-03-10	AstraZeneca AB	<input type="checkbox"/>
NG	11	2005/019172	WO	A1	2005-03-03	AstraZeneca AB	<input type="checkbox"/>
NG	12	2005/018637	WO	A1	2005-03-03	AstraZeneca AB	<input type="checkbox"/>
NG	13	2005/020987	WO	A1	2005-03-10	AstraZeneca AB	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

/Nyemah Grazier/

02/16/2007

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10528612
Filing Date	2005-03-21
First Named Inventor	Michael Butters
Art Unit	1626
Examiner Name	GRAZIER, NYEEMAH
Attorney Docket Number	100837-1P US

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
NG	1	Freeman, S., et al., "Effect of Glucose on Rat and Human Liver Glycogen Phosphorylase Activity and Potency of a Glycogen Phosphoylase Inhibitor," Diabetes, 52, Supp., 1470-P, A340 (2003)	<input type="checkbox"/>
NG	2	Turnbull, A., et al., "Pharmacological Inhibition of Glycogen Phosphorylase (GP) Lowers Plasma Glucose in Rat Models of Type 2 Diabetes," Diabetes, 52, Supp., 1485-P, A343 (2003)	<input type="checkbox"/>
	3	<i>It's negible. Please resubmit</i> Birch, A., et al., "Novel Thienopyrrole Glycogen Phosphorylase Inhibitors: In Vitro SAR and Crystallographic Studies," Poster, Cambridge Med Chem Symposium (Sept 2003)	<input type="checkbox"/>
NG	4	Hudson, S., et al., "The effect of a glycogen phosphorylase inhibitor upon muscle fatigue in anaesthetised rats," J. Physiol., 539:52-53 (2002)	<input type="checkbox"/>
NG	5	Vertigan, H. et al. "Impact of cell glycogen content on modulation of hepatocyte glucose metabolism by pharmacological agents", EASD Munich (2004)	<input type="checkbox"/>
NG	6	Bartlett, J. et al. "In Vitro and In Vivo Profile of Gpi688, a Novel, Potent Inhibitor of Glycogen Phosphorylase", ADA San Diego (2005)	<input type="checkbox"/>
NG	7	Simpson, I. et al. "Novel Orally Active Amino-indan Inhibitors of Glycogen Phosphorylase", Cambridge Med Chem Conference, (Sept 2005). Poster EOM	<input type="checkbox"/>
NG	8	Green, A R. et al. "The Glycogenic Action of Protein Targeting to Glycogen in Hepatocytes Involves Multiple Mechanisms Including Phosphorylase Inactivation and Glycogen Synthase Translocation", J Biol Chem, 279(45), 46474-46482 (2004)	<input type="checkbox"/>
NG	9	Roberts, P A. et al. " The temporal relationship between glycogen phosphorylase and activation of the pyruvate dehydrogenase complex during adrenaline infusion in resting canine skeletal muscle", J Physiology-London 545(1), 297-304 (2002)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

/Nyeemah Grazier/

02/16/2007

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Application Number	10528612
		Filing Date	2005-03-21
		First Named Inventor	Michael Butters
		Art Unit	1626
		Examiner Name	GRAZIER, NYEEMAH
		Attorney Docket Number	100837-1P US

EXAMINER SIGNATURE

Examiner Signature	/Nyeemah Grazier/	Date Considered	02/16/2007
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			
<small> ¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached. </small>			